• Langley Road, Brighton, MA
  • 416-402-8274

Companion Diagnostic to Evaluate Cancer Treatment

Companion Diagnostic to Evaluate Cancer Treatment

One Million Solutions in Health™ is pleased to announce that a new companion diagnostic to evaluate cancer treatment, based on Dr. Peng Loh’s work from the NIH, received the top designation of Blockbuster. This means the technology was highly ranked in both its Market or Partner Readiness and its Value Proposition to the Marketplace.

One Million Solutions in Health™ has established a one-of-a-kind, new partnership with the United States’ Office of Technology Transfer at the National Institutes of Health (NIH) to increase awareness and understanding of NIH technologies among potential partners in the life science and healthcare industries. 

The Signature Square™ program brings together Subject Matter Experts to evaluate new or established scientific technology. The Signature Square™ program provides feedback to commercial providers and academics on technology in the healthcare or life science industry. The vendor or scientist discusses their solution during a live webinar presentation with an audience of relevant Subject Matter Experts. In Dr. Loh’s case, the experts were from diagnostic, pharmaceutical and biotechnology companies, along with other academic scientists from around the world who evaluated this companion diagnostic to evaluate cancer treatment.

The Signature Square™ evaluation is based on several criteria that summarize a new or established technology’s Market Readiness and Value Proposition to the Marketplace. The final outcome of each evaluation results in a ranking: Blockbuster, Upstart, Novel or Innovator. This is an opportunity for technology providers to receive direct evaluation, which can be used to inform potential investors and partners.

“The Signature Square program gave Dr. Loh excellent feedback the first time she participated in the program,” stated Dawn Van Dam, President and CEO of One Million Solutions in Health. “Because her technology has multiple applications, it was important to present it to a diverse audience. In this way, she can better direct the Road Map for her technology based on the feedback of the Subject Matter Experts from various backgrounds.”

Dr. Loh’s technology is a new biomarker that uniquely measures the progression and aggressiveness of a patient’s cancer. This biomarker also predicts recurrence and metastasis in various cancers, including liver, colorectal, adrenal and lung cancer. An important application of this biomarker is using it as a companion diagnostic to evaluate cancer treatment. 

“It is a highly relevant issue in cancer today. Dr. Loh is original and well-informed.”
– Feedback from a Subject Matter Expert

Dr. Loh received positive and constructive feedback from the industry, which will allow her to continue to develop her science and find partners to bring it to commercial use. Dr. Loh has received a final report detailing the Subject Matter Expert’s feedback.

For those interested in working with Dr. Loh to bring this companion diagnostic to evaluate cancer treatment to the market, please contact Dawn Van Dam, President of One Million Solutions in Health to be put in touch with the appropriate NIH contacts.

Alternatively, if you would like to see the details of the full Report and a recording of the Signature Square™ presentation, please contact us for more details on how individuals or companies can join the Technology Evaluation Consortium™ and have full access to all of our Signature Square™ evaluations.




The goal of One Million Solutions in Health™ is to shape health care by sharing solutions and, importantly, to accelerate the discovery, development and delivery … of innovative cures, treatments and preventative measures for patients around the world.

In this next year, we will be reviewing 1000’s of new solutions and new scientific discoveries. By engaging scientists, entrepreneurs, investors, innovators, industry experts, health care professionals, and patients across various disciplines, and from around the world, we can utilize the power of the internet to disrupt things in a positive and transformative way to accelerate the movement of new solutions and scientific discoveries from the scientist to the patient.

We are on our way towards accelerating high-potential innovations, catalyzing investment and increasing awareness of, and support for, transformative ideas to improve health and save lives. By facilitating efforts to ensure organizations can Connect, Learn + Share, Innovate and Collaborate, our vision is to improve health care delivery, accelerate life sciences research and share patient and consumer-focused ideas and solutions.

As a not-for-profit, we welcome your participation and are thrilled to have you be a part of this transformative journey!



The Technology Evaluation Consortium™ from One Million Solutions in Health™ is dedicated to improving and accelerating life sciences R&D and health care outcomes. The Technology Evaluation Consortium brings together life sciences and/or health care companies and industry vendors or scientists, and other relevant partners (e.g., government and Universities), to evaluate and validate technologies or services in a collaborative environment.

The model empowers technology providers/scientists and industry end-users to collectively assess a number of solutions in a cost-effective manner, producing a depth and breadth of results that no company can achieve alone. Our mission is to triage and streamline new technology consideration for the industry and to be the place for the industry to conduct their evaluations and validations.



Dr. Y. Peng Loh is the head of the Section on Cellular Neurobiology, Program on Developmental Neuroscience, NICHD. She and her group study the cell biology of endocrine and neuroendocrine cells, focusing on the mechanisms of biosynthesis and intracellular trafficking of peptide hormones and neuropeptides and their processing enzymes, the regulation of dense-core secretory granule biogenesis, and the physiological roles of the prohormone processing enzyme carboxypeptidase E, and peptides derived from the neuroendocrine protein , chromogranin A. Her studies have elucidated molecular mechanisms governing protein trafficking to the regulated secretory pathway and identified players and mechanisms that control secretory granule biogenesis and transport in endocrine and neuroendocrine cells and neurons. Her research has also provided a better understanding of diseases such as diabetes, obesity and neurodegeneration.

Recently, she and her team have discovered a splice isoform of the enzyme, carboxypeptidase E (CPE-ΔN) that is highly expressed in different types of metastatic tumor cells and is an inducer of tumor growth and metastasis. Clinical studies so far have shown that CPE-∆N is a very promising powerful biomarker for predicting future metastasis, and a potential therapeutic target for different malignant cancers.


Media Contact

Dawn Van Dam

President and CEO